Eton Pharmaceuticals Net Worth
Eton Pharmaceuticals Net Worth Breakdown | ETON |
Eton Pharmaceuticals Net Worth Analysis
Eton Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eton Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eton Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eton Pharmaceuticals' net worth analysis. One common approach is to calculate Eton Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eton Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eton Pharmaceuticals' net worth. This approach calculates the present value of Eton Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eton Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eton Pharmaceuticals' net worth. This involves comparing Eton Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eton Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Eton Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eton Pharmaceuticals' net worth research are outlined below:
| Eton Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 39.01 M. Net Loss for the year was (3.82 M) with profit before overhead, payroll, taxes, and interest of 14.32 M. | |
| Latest headline from simplywall.st: Eton Pharmaceuticals Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags |
Eton Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eton Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eton Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Eton Pharmaceuticals Target Price Consensus
Eton target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Eton Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Eton analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Eton stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Eton Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEton Pharmaceuticals Target Price Projection
Eton Pharmaceuticals' current and average target prices are 14.22 and 13.00, respectively. The current price of Eton Pharmaceuticals is the price at which Eton Pharmaceuticals is currently trading. On the other hand, Eton Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Eton Pharmaceuticals Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Eton Pharmaceuticals Target Price
Know Eton Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eton Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eton Pharmaceuticals backward and forwards among themselves. Eton Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eton Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-12-31 | 239 K | Wasatch Advisors Lp | 2024-12-31 | 231.3 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 214.9 K | Paradigm Capital Management, Inc. | 2024-12-31 | 200 K | Renaissance Technologies Corp | 2024-12-31 | 193.1 K | Susquehanna International Group, Llp | 2024-12-31 | 192.3 K | Acuitas Investments, Llc | 2024-12-31 | 185.8 K | Millennium Management Llc | 2024-12-31 | 138.9 K | Ubs Group Ag | 2024-12-31 | 135.4 K | Opaleye Management Inc | 2024-12-31 | 2.9 M | Ecor1 Capital, Llc | 2024-12-31 | 1.8 M |
Follow Eton Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 236.92 M.Market Cap |
|
Project Eton Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.16) | (0.16) |
When accessing Eton Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eton Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eton Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Eton Pharmaceuticals' management efficiency
Eton Pharmaceuticals has return on total asset (ROA) of (0.125) % which means that it has lost $0.125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.443) %, meaning that it created substantial loss on money invested by shareholders. Eton Pharmaceuticals' management efficiency ratios could be used to measure how well Eton Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of March 2025, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to drop to -0.05. At this time, Eton Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 21st of March 2025, Net Tangible Assets is likely to grow to about 12.2 M, while Non Currrent Assets Other are likely to drop about 10.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.94 | 1.22 | |
| Tangible Book Value Per Share | (0.40) | (0.38) | |
| Enterprise Value Over EBITDA | (127.11) | (133.46) | |
| Price Book Value Ratio | 14.12 | 14.83 | |
| Enterprise Value Multiple | (127.11) | (133.46) | |
| Price Fair Value | 14.12 | 14.83 | |
| Enterprise Value | 55 M | 71.5 M |
The management team at Eton Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 10.5443 | Revenue | Quarterly Revenue Growth (0.24) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eton Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eton Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eton Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eton Pharmaceuticals Corporate Filings
10K | 18th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 7th of March 2025 An amendment to a previously filed Form 8-K | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Eton Pharmaceuticals Earnings Estimation Breakdown
The calculation of Eton Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eton Pharmaceuticals is estimated to be -0.0425 with the future projection ranging from a low of -0.045 to a high of -0.0425. Please be aware that this consensus of annual earnings estimates for Eton Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.04 Lowest | Expected EPS | -0.04 Highest |
Eton Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Eton Pharmaceuticals' value are higher than the current market price of the Eton Pharmaceuticals stock. In this case, investors may conclude that Eton Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Eton Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 3 | 7.98% | 0.0236 | -0.0425 | -0.26 |
Eton Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Eton Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Eton Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Eton Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Eton Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Eton Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Eton Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Eton Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Eton Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -0.07 | -0.12 | -0.05 | 71 | ||
2024-05-09 | 2024-03-31 | -0.07 | -0.03 | 0.04 | 57 | ||
2024-03-14 | 2023-12-31 | -0.04 | -0.09 | -0.05 | 125 | ||
2023-11-09 | 2023-09-30 | -0.1 | -0.02 | 0.08 | 80 | ||
2023-08-10 | 2023-06-30 | -0.09 | 0.15 | 0.24 | 266 | ||
2023-05-11 | 2023-03-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2023-03-16 | 2022-12-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2022-11-10 | 2022-09-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2022-08-11 | 2022-06-30 | 0.03 | -0.06 | -0.09 | 300 | ||
2022-05-12 | 2022-03-31 | -0.08 | -0.21 | -0.13 | 162 | ||
2022-03-16 | 2021-12-31 | 0.19 | 0.04 | -0.15 | 78 | ||
2021-11-15 | 2021-09-30 | -0.13 | -0.24 | -0.11 | 84 | ||
2021-08-16 | 2021-06-30 | -0.14 | -0.1 | 0.04 | 28 | ||
2021-05-13 | 2021-03-31 | 0.19 | 0.19 | 0.0 | 0 | ||
2021-03-16 | 2020-12-31 | -0.26 | -0.32 | -0.06 | 23 | ||
2020-11-12 | 2020-09-30 | -0.25 | -0.31 | -0.06 | 24 | ||
2020-08-12 | 2020-06-30 | -0.26 | -0.23 | 0.03 | 11 | ||
2020-05-14 | 2020-03-31 | -0.22 | -0.5 | -0.28 | 127 | ||
2020-03-05 | 2019-12-31 | -0.26 | -0.15 | 0.11 | 42 | ||
2019-11-14 | 2019-09-30 | -0.25 | -0.28 | -0.03 | 12 | ||
2019-08-06 | 2019-06-30 | -0.28 | -0.18 | 0.1 | 35 | ||
2018-08-10 | 2018-06-30 | 0 | -0.23 | -0.23 | 0 |
Eton Pharmaceuticals Corporate Management
| Danka Radosavljevic | Senior Operations | Profile | |
| James CPA | Treasurer CFO | Profile | |
| Kevin Guthrie | Executive Operations | Profile | |
| Scott Grossenbach | Senior Operations | Profile | |
| Ingrid Hoos | Senior Affairs | Profile | |
| Ipek ErdoganTrinkaus | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.